MITAC-COMPUTING
27.5.2019 04:02:06 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st , Booth # L0631a in Taipei, Taiwan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/
“The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2nd gen Intel® Xeon® Scalable processors and are designed to help enterprises and data center service providers capture, process, and analyze big data faster and at a more powerful rate than ever before.”
2nd Gen Intel Xeon Scalable Processors Empower TYAN HPC and Storage Platforms to Deliver Leading Performance
TYAN’s HPC and storage server platforms are built on the 2nd gen Intel Xeon Scalable processors with accompanying new innovations of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable faster machine learning application execution and accelerated workload processing and service delivery. The new Thunder HX FT83-B7119 is an AI-optimized platform and is ideal for AI training and inference applications. The system supports for up to 3TB of memory and 12 hot-swappable 3.5” drives in a 4U enclosure.
The Thunder SX FA100-B7118 is TYAN’s flagship storage server supporting dual-socket 2nd gen Intel Xeon Scalable processors and 100 3.5” drives in a 4U rackmount form factor. The platform is designed for both cold storage and large-scale object storage applications such as Lustre. TYAN’s Thunder SX TN76-B7102 is 2U dual-socket 2nd gen Intel Xeon Scalable processor-based storage platform. With support for up to 24 DDR4 DIMM slots and maximum expansion up to 8 standard PCIe slots, the TN76-B7102 can fully address the high memory capacity required by data virtualization and in-memory databases.
For the high-performance storage segment, the Thunder SX GT62H-B7106 is a 1U server platform with support hot-swap all-flash drives. The GT62H-B7106 features dual-socket 2nd gen Intel Xeon Scalable processors, 16 DIMM slots, two low profile PCIe x16 slots, and 10 U.2 NVMe drive bays. This platform offers maximum storage performance and large memory capacity and is ideal for edge server applications.
The new Thunder SX GT90-B7113 features support for dual 2nd gen Intel Xeon Scalable processors, 12 hot-swap 3.5” drives mounted to a service drawer and 4 hot-swap NVMe U.2 drive bays in a 35” deep 1U chassis. The platform perfectly matches CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
Intel ® Xeon ® D-2100 and Intel ® Xeon ® E-2100 Processor-based Platforms to Maximize Compute Performance and Efficiency for Cloud and Storage
Powered by the Intel Xeon D-2100 processors, TYAN Thunder SX TE70-B5546 and Thunder SX TE73-B5546 platforms are optimized to deliver rich features of low-power, high-density and high-availability. These two systems are both in 2U dual-node form factor with dual-controller, dual-path redundant design for high availability requirement and support dual-port SAS/NVMe storage functions for today’s high available data-intensive storage environments. TE70-B5546 supports up to 24 2.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2; TE73-B5546 supports up to 12 3.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2.
Moreover, taking full advantage of Intel Xeon E-2100 processors, TYAN offers increased reliability, security, performance, and affordability for its entry server lineup. TYAN’s Thunder CX GT24E-B5556 is a 1U single-socket Intel Xeon E-2100 processor-based edge cloud server. With support for up to 4 DDR4 DIMM slots, 3 PCIe slots, and dual 10GBase-T Ethernet ports, the platform is optimized for cost-effective cloud gaming applications. The Thunder CX GX38-B5550 is 1U single-socket Intel Xeon E-2100 processor-based compact sever with shallow chassis and support for 2 3.5” internal SATA drive bays for IoT applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005002/en/
Contact:
MiTAC Computing Technology Corporation/ TYAN Business Unit Fenny Chen fenny.chen@tyan.com.tw
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom